Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients With Platinum-Resistant Recurrent Ovarian Cancer By Ogkologos - April 23, 2026 203 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-ov65/KEYNOTE-B96 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Azacitidine May 3, 2021 FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia November 3, 2021 Inseparable Couples Dies 33 Hours Apart After 68 Years Of Marriage:... December 5, 2019 Even If Insured, People with Advanced Cancer Often Face Financial Problems January 26, 2022 Load more HOT NEWS Study Shows Supplements Increase Risk of Relapse and Death in Breast... Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC... Reunión anual de la American Society of Clinical Oncology de 2023:... Black In Cancer – That Cancer Conversation
